KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
128 hedge funds and large institutions have $640M invested in KalVista Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 45 increasing their positions, 36 reducing their positions, and 24 closing their positions.
22,781% more call options, than puts
Call options by funds: $15.8M | Put options by funds: $69K
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
37% more capital invested
Capital invested by funds: $467M → $640M (+$173M)
25% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 36
8% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 24
1.22% less ownership
Funds ownership: 111.68% → 110.46% (-1.2%)
2% less funds holding
Funds holding: 130 → 128 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$11.1M |
| 2 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$7.69M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$5.94M |
| 4 |
VA
VR Adviser
New York
|
+$4.64M |
| 5 |
JP Morgan Chase
New York
|
+$3.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Boxer Capital Management
San Diego,
California
|
-$13.5M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$7.89M |
| 3 |
SC
Stempoint Capital
New York
|
-$6.18M |
| 4 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
-$3.08M |
| 5 |
State Street
Boston,
Massachusetts
|
-$3.03M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Zurich Cantonal Bank
Zurich,
Switzerland
| – | -$9.86K | -1,164 | Closed |
|
|
RS
152
R Squared
Central,
Hong Kong
| – | -$932 | -110 | Closed |
|
KALV Hedge Fund Activity: Q1 2025 in Review
128 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q1 2025, worth a combined $640M — up 37% from $467M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of KALV and 22 opened new positions — a net loss of 2 holders — while 36 trimmed existing stakes and 45 added.
The largest buyer was Silverarc Capital Management, adding an estimated $11.1M. The largest seller was Boxer Capital Management, exiting entirely with an estimated $13.5M sold.
- 128 institutional investors held KalVista Pharmaceuticals (KALV) as of Q1 2025, down from 130 in Q4 2024.
- Funds reported $640M of KalVista Pharmaceuticals stock for Q1 2025, up 37% quarter-over-quarter.
- 22 funds opened new KalVista Pharmaceuticals positions in Q1 2025 and 24 closed out, a net change of -2 holders.
- The largest KalVista Pharmaceuticals buyer in Q1 2025 was Silverarc Capital Management, an estimated $11.1M added.
- The largest KalVista Pharmaceuticals seller in Q1 2025 was Boxer Capital Management, an estimated $13.5M sold.
Based on aggregated 13F filings for Q1 2025.